Nothing Special   »   [go: up one dir, main page]

LT2935331T - Prolaktino receptorių surišantys baltymai ir jų panaudojimas - Google Patents

Prolaktino receptorių surišantys baltymai ir jų panaudojimas

Info

Publication number
LT2935331T
LT2935331T LTEP13821368.1T LT13821368T LT2935331T LT 2935331 T LT2935331 T LT 2935331T LT 13821368 T LT13821368 T LT 13821368T LT 2935331 T LT2935331 T LT 2935331T
Authority
LT
Lithuania
Prior art keywords
binding proteins
receptor binding
prolactin receptor
prolactin
proteins
Prior art date
Application number
LTEP13821368.1T
Other languages
English (en)
Inventor
Mark Anderson
Jieyi Wang
Archana THAKUR
Debra Chao
Chung-Ming Hsieh
Qian Zhang
Edward Reilly
Enrico DIGIAMMARINO
Kenton Longenecker
Russell JUDGE
David Egan
Charles Hutchins
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of LT2935331T publication Critical patent/LT2935331T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01SRADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S13/00Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
    • G01S13/86Combinations of radar systems with non-radar systems, e.g. sonar, direction finder
    • G01S13/867Combination of radar systems with cameras
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01SRADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S13/00Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
    • G01S13/88Radar or analogous systems specially adapted for specific applications
    • G01S13/91Radar or analogous systems specially adapted for specific applications for traffic control
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06VIMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00Scenes; Scene-specific elements
    • G06V20/50Context or environment of the image
    • G06V20/56Context or environment of the image exterior to a vehicle by using sensors mounted on the vehicle
    • G06V20/58Recognition of moving objects or obstacles, e.g. vehicles or pedestrians; Recognition of traffic objects, e.g. traffic signs, traffic lights or roads
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/0104Measuring and analyzing of parameters relative to traffic conditions
    • G08G1/0125Traffic data processing
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/015Detecting movement of traffic to be counted or controlled with provision for distinguishing between two or more types of vehicles, e.g. between motor-cars and cycles
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/04Detecting movement of traffic to be counted or controlled using optical or ultrasonic detectors
    • GPHYSICS
    • G08SIGNALLING
    • G08GTRAFFIC CONTROL SYSTEMS
    • G08G1/00Traffic control systems for road vehicles
    • G08G1/01Detecting movement of traffic to be counted or controlled
    • G08G1/042Detecting movement of traffic to be counted or controlled using inductive or magnetic detectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Radar, Positioning & Navigation (AREA)
  • Remote Sensing (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Electromagnetism (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Multimedia (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP13821368.1T 2012-12-24 2013-12-23 Prolaktino receptorių surišantys baltymai ir jų panaudojimas LT2935331T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745707P 2012-12-24 2012-12-24
PCT/US2013/077452 WO2014105810A1 (en) 2012-12-24 2013-12-23 Prolactin receptor binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
LT2935331T true LT2935331T (lt) 2018-06-25

Family

ID=49956483

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13821368.1T LT2935331T (lt) 2012-12-24 2013-12-23 Prolaktino receptorių surišantys baltymai ir jų panaudojimas

Country Status (29)

Country Link
US (4) US9725515B2 (lt)
EP (2) EP3363817A1 (lt)
JP (3) JP6382221B2 (lt)
KR (1) KR20150100881A (lt)
CN (1) CN105102480B (lt)
AU (3) AU2013370548B2 (lt)
BR (1) BR112015015289A2 (lt)
CA (1) CA2896058A1 (lt)
CY (1) CY1120286T1 (lt)
DK (1) DK2935331T3 (lt)
ES (1) ES2671506T3 (lt)
HK (1) HK1216257A1 (lt)
HR (1) HRP20180822T1 (lt)
HU (1) HUE037586T2 (lt)
IL (1) IL239502B (lt)
LT (1) LT2935331T (lt)
ME (1) ME03075B (lt)
MX (1) MX359532B (lt)
NO (1) NO2968312T3 (lt)
PL (1) PL2935331T3 (lt)
PT (1) PT2935331T (lt)
RS (1) RS57259B1 (lt)
RU (2) RU2018129572A (lt)
SG (1) SG11201504943QA (lt)
SI (1) SI2935331T1 (lt)
TR (1) TR201807416T4 (lt)
TW (3) TW201920245A (lt)
WO (1) WO2014105810A1 (lt)
ZA (1) ZA201504803B (lt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
LT2935331T (lt) 2012-12-24 2018-06-25 Abbvie Inc. Prolaktino receptorių surišantys baltymai ir jų panaudojimas
TWI641620B (zh) * 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
AR098221A1 (es) 2013-11-04 2016-05-18 Pfizer Conjugados de anticuerpo anti-efna4-fármaco
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
DK3218005T5 (da) 2014-11-12 2024-10-14 Seagen Inc Glycan-interagerende forbindelser og anvendelsesfremgangsmåder
JP6914193B2 (ja) 2015-06-24 2021-08-04 Jcrファーマ株式会社 Bdnfを含む融合蛋白質
CN107849555B (zh) * 2015-06-24 2022-01-04 Jcr制药股份有限公司 通过血脑屏障的抗人转铁蛋白受体抗体
CN108472369A (zh) 2015-11-03 2018-08-31 詹森生物科技公司 抗cd38抗体的皮下制剂及其用途
CN116217729A (zh) * 2015-11-12 2023-06-06 思进公司 聚糖相互作用化合物及使用方法
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN106265480A (zh) * 2016-09-03 2017-01-04 山西纳安生物科技有限公司 纳米抗体阴道给药系统及制备方法和应用
KR102561356B1 (ko) 2016-09-14 2023-08-03 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도
MX2019005330A (es) 2016-11-08 2019-09-11 Regeneron Pharma Esteroides y conjugados de proteinas de los mismos.
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2017366873A1 (en) 2016-11-29 2019-06-13 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018124121A1 (ja) 2016-12-26 2018-07-05 Jcrファーマ株式会社 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体
CN110114078B (zh) * 2016-12-28 2024-01-30 Jcr制药股份有限公司 冷冻干燥制剂
CA3054939A1 (en) 2017-03-03 2018-09-07 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
MX2019011130A (es) * 2017-03-20 2019-11-05 Vaccinex Inc Tratamiento del cancer con un anticuerpo semaforina-4d en combinacion con un agente de modulacion epigenetica.
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗-prlr抗體藥物軛合物(adc)及其用途
US11866506B2 (en) 2017-04-21 2024-01-09 Mellitus, Llc Anti-CD59 antibodies
IL270594B2 (en) 2017-05-18 2024-06-01 Regeneron Pharma Protein conjugates - a drug of cyclodextrin
US11351140B2 (en) 2017-05-19 2022-06-07 J. Craig Venter Institute Resolvin mimetic antibodies and uses thereof
BR112019023789A2 (pt) * 2017-08-03 2020-07-28 Alector Llc anticorpos anti-cd33 e métodos de uso dos mesmos
IL274427B2 (en) 2017-11-07 2024-11-01 Regeneron Pharmaceuticals Inc Hydrophilic linkers for drug-antibody conjugates
JP7366028B2 (ja) 2018-01-08 2023-10-20 レゲネロン ファーマシューティカルス,インコーポレーテッド ステロイド及びその抗体コンジュゲート
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
US11505610B2 (en) 2018-04-06 2022-11-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
BR112020022400A2 (pt) 2018-05-09 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpos anti-msr1 e métodos de uso dos mesmos
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
CA3108022A1 (en) * 2018-07-31 2020-02-06 Cullinan Mica Corp. Anti-mica/b antibodies that block mica/b shedding and methods of use
CN113748130A (zh) * 2019-03-12 2021-12-03 大学保健网 Tsg-6抗体和其用途
EP3757217A1 (en) * 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
JP7440122B2 (ja) * 2019-07-12 2024-02-28 明済生物製薬(北京)有限公司 Cldn18.2抗体及びその用途
RU2722398C1 (ru) * 2019-08-09 2020-05-29 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к БТШ70
CA3156803A1 (en) 2019-10-03 2021-04-08 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2021222944A1 (en) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
AU2022293581A1 (en) * 2021-06-18 2024-01-25 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
CA3234409A1 (en) * 2021-10-27 2023-05-04 Luke G. BURMAN Compositions and methods comprising anti-nrp2a antibodies
CN115417908B (zh) * 2022-09-01 2024-06-18 英科新创(苏州)生物科技有限公司 雌二醇衍生物、其制备方法、检测试剂盒及雌二醇定量检测方法
CN115353541B (zh) * 2022-09-01 2024-06-18 英科新创(苏州)生物科技有限公司 雌二醇衍生物的制备方法,中间体、其制备方法和应用
CN117694469B (zh) * 2024-02-02 2024-04-23 潍坊新希望六和饲料科技有限公司 一种改善褐壳鸡蛋蛋壳质量的饲料添加剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867187B2 (en) 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
US7507716B2 (en) 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
CA2932012A1 (en) * 2006-08-18 2008-02-21 Novartis Ag Prlr-specific antibody and uses thereof
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
JP5963443B2 (ja) 2009-02-26 2016-08-03 オンコリックス, インコーポレイテッド がん幹細胞を可視化・排除するための組成物および方法
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011151405A1 (en) 2010-06-04 2011-12-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence
WO2012136519A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
LT2935331T (lt) 2012-12-24 2018-06-25 Abbvie Inc. Prolaktino receptorių surišantys baltymai ir jų panaudojimas
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
CN106573074B (zh) 2014-06-02 2022-04-12 里珍纳龙药品有限公司 生物活性分子偶联物、试剂和制备方法及其治疗用途

Also Published As

Publication number Publication date
CA2896058A1 (en) 2014-07-03
IL239502A0 (en) 2015-08-31
PT2935331T (pt) 2018-06-04
JP2016504035A (ja) 2016-02-12
TR201807416T4 (tr) 2018-06-21
AU2013370548B2 (en) 2019-01-17
US20170022281A1 (en) 2017-01-26
CN105102480A (zh) 2015-11-25
EP2935331A1 (en) 2015-10-28
NO2968312T3 (lt) 2018-06-30
SI2935331T1 (en) 2018-06-29
TW201920283A (zh) 2019-06-01
US10184003B2 (en) 2019-01-22
IL239502B (en) 2019-11-28
HK1216257A1 (zh) 2016-10-28
TW201920245A (zh) 2019-06-01
DK2935331T3 (en) 2018-06-06
RU2015130605A (ru) 2017-01-24
ZA201504803B (en) 2020-02-26
RU2664463C2 (ru) 2018-08-17
AU2019202725A1 (en) 2019-05-16
EP2935331B1 (en) 2018-02-28
EP3363817A1 (en) 2018-08-22
MX359532B (es) 2018-10-01
PL2935331T3 (pl) 2018-07-31
JP2020188775A (ja) 2020-11-26
US20190153110A1 (en) 2019-05-23
SG11201504943QA (en) 2015-07-30
HRP20180822T1 (hr) 2018-08-10
US20210074147A1 (en) 2021-03-11
TW201441259A (zh) 2014-11-01
RU2018129572A (ru) 2018-10-12
US9725515B2 (en) 2017-08-08
MX2015008299A (es) 2016-02-11
AU2021202954A1 (en) 2021-06-03
HUE037586T2 (hu) 2018-09-28
KR20150100881A (ko) 2015-09-02
US20210312797A9 (en) 2021-10-07
JP2018198608A (ja) 2018-12-20
CN105102480B (zh) 2019-04-16
BR112015015289A2 (pt) 2017-08-15
AU2013370548A1 (en) 2015-07-09
CY1120286T1 (el) 2019-07-10
ME03075B (me) 2019-01-20
ES2671506T3 (es) 2018-06-06
WO2014105810A1 (en) 2014-07-03
TWI646106B (zh) 2019-01-01
US20140227294A1 (en) 2014-08-14
RS57259B1 (sr) 2018-08-31
JP6382221B2 (ja) 2018-08-29

Similar Documents

Publication Publication Date Title
HK1216257A1 (zh) 催乳素受體結合蛋白及其用途
HK1205136A1 (en) Cdim binding proteins and uses thereof cdim
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
HK1208687A1 (en) Rspo3 binding agents and uses thereof rspo3
ZA201405554B (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
HK1198832A1 (en) Fn14 binding proteins and uses thereof fn14
EP2558500A4 (en) PI16 BINDING PROTEINS AND THEIR USE
HK1210182A1 (en) Anti-prokineticin receptor (prokr) antibodies and uses thereof (prokr)
GB201208372D0 (en) Antibodies and uses thereof
EP2817324A4 (en) NEMO BOND DOMAIN FUSION PROTEINS
GB201203944D0 (en) Binding polypeptides